EXPRESS: Intravenous Iron Infusions in Pediatric Patients: A Retrospective Review of Efficacy and Safety.

Pediatric iron deficiency anemia (IDA) is often treated with oral iron supplementation as the first-line therapy despite poor adherence. This single-institution retrospective chart review was conducted to assess the safety, efficacy, and adherence of intravenous (IV) iron infusions compared to oral iron in pediatric patients who had failed a trial of oral iron supplementation. We reviewed medical records of patients aged 1-21 with IDA who received at least one IV iron infusion at Cooper University Hospital between 2016 and 2021. Paired t-tests compared pre-infusion and post-infusion hematologic indices of hemoglobin (Hgb), mean corpuscular volume (MCV), red blood cell count (RBC), red cell distribution width (RDW), ferritin, total iron binding capacity (TIBC), iron stores, and iron saturation (% sat). We compared adherence and adverse reactions to both oral iron supplementation and IV iron infusions using a McNemar test. A total of 107 subjects were included (mean age of 12.7 years). Hemoglobin, ferritin, iron, and iron saturation between pre-infusion and post-final infusion significantly improved (p <0.001). Hemoglobin, ferritin and iron improved when subcategorizing by race and etiology of IDA. Adherence to IV iron infusions (70.1%) was significantly greater than adherence to oral iron therapy (43.0%). There were also significantly fewer adverse effects with IV iron infusions (3.7%) compared to oral iron (77.9%). We demonstrated the safety, efficacy, and improved adherence of IV iron infusions compared to oral iron supplementation for treatment of pediatric IDA in patients who were unable to tolerate oral iron supplementation.